
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1969552/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Establishment of the upstream processing for renewable production of hydrogen using vermicomposting-tea and molasses as substrate. Waste Management, 2022, 139, 279-289.	3.7	4
2	Only a small fraction of cells produce assembled capsids during transfectionâ€based manufacturing of adenoâ€associated virus vectors. Biotechnology and Bioengineering, 2022, 119, 1685-1690.	1.7	10
3	Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use. Viruses, 2022, 14, 975.	1.5	9
4	Overview of recent advances in Vero cells genomic characterization and engineering for highâ€ŧhroughput vaccine manufacturing. Clinical and Translational Discovery, 2022, 2, .	0.2	5
5	Advancements in molecular design and bioprocessing of recombinant adenoâ€associated virus gene delivery vectors using the insectâ€cell baculovirus expression platform. Biotechnology Journal, 2021, 16, e2000021.	1.8	26
6	Cross-validation of ELISA and a portable surface plasmon resonance instrument for IgG antibody serology with SARS-CoV-2 positive individuals. Analyst, The, 2021, 146, 4905-4917.	1.7	28
7	Characterization of Extracellular Vesicles Secreted in Lentiviral Producing HEK293SF Cell Cultures. Viruses, 2021, 13, 797.	1.5	9
8	Bioreactor production of rVSVâ€based vectors in Vero cell suspension cultures. Biotechnology and Bioengineering, 2021, 118, 2649-2659.	1.7	15
9	Development and Validation of an Anion Exchange High-Performance Liquid Chromatography Method for Analysis of Empty Capsids and Capsids Encapsidating Genetic Material in a Purified Preparation of Recombinant Adeno-Associated Virus Serotype 5. Human Gene Therapy, 2021, 32, 1390-1402.	1.4	11
10	Recent advances and current challenges in process intensification of cell cultureâ€based influenza virus vaccine manufacturing. Canadian Journal of Chemical Engineering, 2021, 99, 2525-2535.	0.9	7
11	Development of a scalable and robust AEX method for enriched rAAV preparations in genome-containing VCs of serotypes 5, 6, 8, and 9. Molecular Therapy - Methods and Clinical Development, 2021, 21, 341-356.	1.8	38
12	Critical Assessment of Purification and Analytical Technologies for Enveloped Viral Vector and Vaccine Processing and Their Current Limitations in Resolving Co-Expressed Extracellular Vesicles. Vaccines, 2021, 9, 823.	2.1	14
13	Vectored-Vaccine Platforms Enabled Rapid Development of Safe and Effective Vaccines in Response to COVID-19 Pandemic Situation. Vaccines, 2021, 9, 722.	2.1	1
14	Haplotype-resolved de novo assembly of the Vero cell line genome. Npj Vaccines, 2021, 6, 106.	2.9	14
15	A Four-Step Purification Process for Gag VLPs: From Culture Supernatant to High-Purity Lyophilized Particles. Vaccines, 2021, 9, 1154.	2.1	9
16	Handling Massive Proportion of Missing Labels in Multivariate Long-Term Time Series Forecasting. Journal of Physics: Conference Series, 2021, 2090, 012170.	0.3	1
17	Process Development for Newcastle Disease Virus-Vectored Vaccines in Serum-Free Vero Cell Suspension Cultures. Vaccines, 2021, 9, 1335.	2.1	15
18	Adenoâ€Associated Viral Vectors for Homologyâ€Directed Generation of CARâ€T Cells. Biotechnology Journal, 2020, 15, e1900286.	1.8	9

#	Article	IF	CITATIONS
19	Rapid In-Process Monitoring of Lentiviral Vector Particles by High-Performance Liquid Chromatography. Molecular Therapy - Methods and Clinical Development, 2020, 18, 803-810.	1.8	9
20	Rapid High-Yield Production of Functional SARS-CoV-2 Receptor Binding Domain by Viral and Non-Viral Transient Expression for Pre-Clinical Evaluation. Vaccines, 2020, 8, 654.	2.1	32
21	Establishing a Robust Manufacturing Platform for Recombinant Veterinary Vaccines: An Adenovirus-Vector Vaccine to Control Newcastle Disease Virus Infections of Poultry in Sub-Saharan Africa. Vaccines, 2020, 8, 338.	2.1	7
22	Vero cell upstream bioprocess development for the production of viral vectors and vaccines. Biotechnology Advances, 2020, 44, 107608.	6.0	66
23	A pooled genome-wide screening strategy to identify and rank influenza host restriction factors in cell-based vaccine production platforms. Scientific Reports, 2020, 10, 12166.	1.6	17
24	Evaluation of novel HIV vaccine candidates using recombinant vesicular stomatitis virus vector produced in serum-free Vero cell cultures. Vaccine, 2020, 38, 7949-7955.	1.7	8
25	Titration methods for rVSV-based vaccine manufacturing. MethodsX, 2020, 7, 100806.	0.7	12
26	Serum-free production of rVSV-ZEBOV in Vero cells: Microcarrier bioreactor versus scale-Xâ,,¢ hydro fixed-bed. Journal of Biotechnology, 2020, 310, 32-39.	1.9	24
27	Lentiviral Vector Production in Suspension Culture Using Serum-Free Medium for the Transduction of CAR-T Cells. Methods in Molecular Biology, 2020, 2086, 77-83.	0.4	6
28	Extended gene expression for Gag VLP production achieved at bioreactor scale. Journal of Chemical Technology and Biotechnology, 2019, 94, 302-308.	1.6	14
29	Development of suspension adapted Vero cell culture process technology for production of viral vaccines. Vaccine, 2019, 37, 6996-7002.	1.7	42
30	Characterization of influenza H1N1 Gag virus-like particles and extracellular vesicles co-produced in HEK-293SF. Vaccine, 2019, 37, 7100-7107.	1.7	22
31	Vaccine Technology VII: Beyond the "decade of vaccines― Vaccine, 2019, 37, 6931-6932.	1.7	1
32	Production of rVSV-ZEBOV in serum-free suspension culture of HEK 293SF cells. Vaccine, 2019, 37, 6624-6632.	1.7	25
33	Achieving High-Yield Production of Functional AAV5 Gene Delivery Vectors via Fedbatch in an Insect Cell-One Baculovirus System. Molecular Therapy - Methods and Clinical Development, 2019, 13, 279-289.	1.8	38
34	Cell Transfection. , 2019, , 383-390.		3
35	PRODUCTION AND PURIFICATION OF VIRAL VECTORS AND SAFETY CONSIDERATIONS RELATED TO THEIR USE. , 2019, , 565-587.		0
36	RNA interference technology to improve the baculovirus-insect cell expression system. Biotechnology Advances, 2018, 36, 443-451.	6.0	20

#	Article	IF	CITATIONS
37	Advancements in mammalian cell transient gene expression (TGE) technology for accelerated production of biologics. Critical Reviews in Biotechnology, 2018, 38, 918-940.	5.1	54
38	Advancements in the design and scalable production of viral gene transfer vectors. Biotechnology and Bioengineering, 2018, 115, 25-40.	1.7	45
39	Large-Scale Transient Transfection of Suspension Mammalian Cells for VLP Production. Methods in Molecular Biology, 2018, 1674, 117-127.	0.4	7
40	Gene Transfer of ZMapp Antibodies Mediated by Recombinant Adeno-Associated Virus Protects Against Ebola Infections. Human Gene Therapy, 2018, 29, 452-466.	1.4	13
41	Manufacturing of recombinant adenoâ€associated viruses using mammalian expression platforms. Biotechnology Journal, 2017, 12, 1600193.	1.8	62
42	Endothelial IL-33 Expression Is Augmented by Adenoviral Activation of the DNA Damage Machinery. Journal of Immunology, 2017, 198, 3318-3325.	0.4	15
43	Accelerated mass production of influenza virus seed stocks in HEK-293 suspension cell cultures by reverse genetics. Vaccine, 2017, 35, 3423-3430.	1.7	12
44	Critical phases of viral production processes monitored by capacitance. Journal of Biotechnology, 2017, 242, 19-29.	1.9	20
45	Process intensification for high yield production of influenza H1N1 Gag virus-like particles using an inducible HEK-293 stable cell line. Vaccine, 2017, 35, 4220-4228.	1.7	25
46	Generation of monoclonal pan-hemagglutinin antibodies for the quantification of multiple strains of influenza. PLoS ONE, 2017, 12, e0180314.	1.1	8
47	Rational plasmid design and bioprocess optimization to enhance recombinant adenoâ€associated virus (AAV) productivity in mammalian cells. Biotechnology Journal, 2016, 11, 290-297.	1.8	38
48	292. Towards Large-Scale Manufacturing of Adeno-Associated Virus by Transient Transfection of HEK293 Suspension Cells in a Stirred Tank Bioreactor Using Serum-Free Medium. Molecular Therapy, 2016, 24, S117-S118.	3.7	3
49	Optimization and scale-up of cell culture and purification processes for production of an adenovirus-vectored tuberculosis vaccine candidate. Vaccine, 2016, 34, 3381-3387.	1.7	21
50	Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: An effective influenza vaccine candidate. Vaccine, 2016, 34, 3371-3380.	1.7	44
51	Current and Emerging Cell Culture Manufacturing Technologies for Influenza Vaccines. BioMed Research International, 2015, 2015, 1-11.	0.9	116
52	Production of Lentiviral Vectors Encoding Recombinant Factor VIII Expression in Serum-Free Suspension Cultures. Brazilian Archives of Biology and Technology, 2015, 58, 923-928.	0.5	3
53	Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems. BMC Biotechnology, 2015, 15, 31.	1.7	57
54	Influence of HEK293 metabolism on the production of viral vectors and vaccine. Vaccine, 2015, 33, 5974-5981.	1.7	33

#	Article	IF	CITATIONS
55	Largeâ€scale adenovirus and poxvirusâ€vectored vaccine manufacturing to enable clinical trials. Biotechnology Journal, 2015, 10, 741-747.	1.8	39
56	Critical review of current and emerging quantification methods for the development of influenza vaccine candidates. Vaccine, 2015, 33, 5913-5919.	1.7	18
57	Particle quantification of influenza viruses by high performance liquid chromatography. Vaccine, 2015, 33, 78-84.	1.7	18
58	Establishment and validation of new complementing cells for production of E1-deleted adenovirus vectors in serum-free suspension culture. Journal of Virological Methods, 2014, 208, 177-188.	1.0	18
59	Manufacturing of viral vectors for gene therapy: part I. Upstream processing. Pharmaceutical Bioprocessing, 2014, 2, 183-203.	0.8	29
60	Production of adeno-associated virus (AAV) serotypes by transient transfection of HEK293 cell suspension cultures for gene delivery. Journal of Virological Methods, 2014, 196, 163-173.	1.0	75
61	Development of a vectored vaccine against Hepatitis E virus. Vaccine, 2014, 32, 2808-2811.	1.7	12
62	Evaluation of homogeneity and genetic stability of REOLYSIN® (pelareorep) by complete genome sequencing of reovirus after large scale production. Applied Microbiology and Biotechnology, 2014, 98, 1763-1770.	1.7	9
63	Analytical technologies for influenza virus-like particle candidate vaccines: challenges and emerging approaches. Virology Journal, 2013, 10, 141.	1.4	61
64	Realâ€ŧime monitoring of influenza virus production kinetics in HEK293 cell cultures. Biotechnology Progress, 2013, 29, 275-284.	1.3	23
65	A novel polyethyleneimine-coated adeno-associated virus-like particle formulation for efficient siRNA delivery in breast cancer therapy: preparation and in vitro analysis. International Journal of Nanomedicine, 2012, 7, 1575.	3.3	26
66	Hyperosmotic pressure on HEK 293 cells during the growth phase, but not the production phase, improves adenovirus production. Journal of Biotechnology, 2012, 157, 228-236.	1.9	15
67	Process optimization and scale-up for production of rabies vaccine live adenovirus vector (AdRG1.3). Vaccine, 2012, 30, 300-306.	1.7	30
68	Probing inhibitory effects of nanocrystalline cellulose: inhibition versus surface charge. Nanoscale, 2012, 4, 1373.	2.8	76
69	An initiative to manufacture and characterize baculovirus reference material. Journal of Invertebrate Pathology, 2011, 107, S113-S117.	1.5	10
70	Manufacturing of Adenovirus Vectors: Production and Purification of Helper Dependent Adenovirus. Methods in Molecular Biology, 2011, 737, 139-156.	0.4	16
71	Insect cell technology is a versatile and robust vaccine manufacturing platform. Expert Review of Vaccines, 2011, 10, 1063-1081.	2.0	106
72	Unraveling the metabolism of HEK-293 cells using lactate isotopomer analysis. Bioprocess and Biosystems Engineering, 2011, 34, 263-273.	1.7	35

#	Article	IF	CITATIONS
73	Development and validation of a HPLC method for the quantification of baculovirus particles. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 61-68.	1.2	14
74	Metabolic and Kinetic analyses of influenza production in perfusion HEK293 cell culture. BMC Biotechnology, 2011, 11, 84.	1.7	60
75	Monitoring lentiviral vector production kinetics using online permittivity measurements. Biochemical Engineering Journal, 2011, 54, 16-25.	1.8	25
76	Overview of Current Scalable Methods for Purification of Viral Vectors. Methods in Molecular Biology, 2011, 737, 89-116.	0.4	53
77	Reassessing culture media and critical metabolites that affect adenovirus production. Biotechnology Progress, 2010, 26, 200-207.	1.3	19
78	An efficient process for the purification of helper-dependent adenoviral vector and removal of helper virus by iodixanol ultracentrifugation. Journal of Virological Methods, 2010, 165, 83-89.	1.0	23
79	Recent progress in lentiviral vector mass production. Biochemical Engineering Journal, 2010, 48, 362-377.	1.8	31
80	Effect of Surface Charge on the Cellular Uptake and Cytotoxicity of Fluorescent Labeled Cellulose Nanocrystals. ACS Applied Materials & Interfaces, 2010, 2, 2924-2932.	4.0	286
81	Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing. Vaccine, 2010, 28, 3661-3671.	1.7	87
82	Improving adenoâ€associated vector yield in high density insect cell cultures. Journal of Gene Medicine, 2010, 12, 157-167.	1.4	36
83	Efficient Human Hematopoietic Cell Transduction Using RD114- and GALV-Pseudotyped Retroviral Vectors Produced in Suspension and Serum-Free Media. Human Gene Therapy, 2009, 20, 966-974.	1.4	52
84	Development of a scalable process for highâ€yield lentiviral vector production by transient transfection of HEK293 suspension cultures. Journal of Gene Medicine, 2009, 11, 868-876.	1.4	117
85	Probing inhibitory effects of destruxins from Metarhizium anisopliae using insect cell based impedance spectroscopy: inhibition vs chemical structure. Analyst, The, 2009, 134, 1447.	1.7	11
86	Rapid and reliable quantification of reovirus type 3 by high performance liquid chromatography during manufacturing of Reolysin®. Journal of Pharmaceutical and Biomedical Analysis, 2008, 48, 598-605.	1.4	6
87	Insights into the Central Metabolism of Spodoptera frugiperda (Sf-9) and Trichoplusia ni BTI-Tn-5B1-4(Tn-5) Insect Cells by Radiolabeling Studies. Biotechnology Progress, 2008, 21, 78-86.	1.3	29
88	Production of Recombinant Adeno-Associated Viral Vectors Using a Baculovirus/Insect Cell Suspension Culture System: From Shake Flasks to a 20-L Bioreactor. Biotechnology Progress, 2008, 21, 154-160.	1.3	66
89	Critical assessment of current adeno-associated viral vector production and quantification methods. Biotechnology Advances, 2008, 26, 73-88.	6.0	63
90	Development of a suspension serum-free helper-dependent adenovirus production system and assessment of co-infection conditions, Journal of Virological Methods, 2008, 148, 106-114	1.0	15

#	Article	lF	CITATIONS
91	Probing Inhibitory Effects of <i>Antrodia camphorata</i> Isolates Using Insect Cell-Based Impedance Spectroscopy: Inhibition vs Chemical Structure. Chemical Research in Toxicology, 2008, 21, 2127-2133.	1.7	39
92	Identification of Host Proteins Associated with Retroviral Vector Particles by Proteomic Analysis of Highly Purified Vector Preparations. Journal of Virology, 2008, 82, 1107-1117.	1.5	61
93	Limiting factors governing protein expression following polyethylenimine-mediated gene transfer in HEK293-EBNA1 cells. Journal of Biotechnology, 2007, 128, 268-280.	1.9	82
94	A simple macroscopic model for the diffusion and adsorption kinetics of r-adenovirus. Biotechnology and Bioengineering, 2007, 98, 239-251.	1.7	7
95	Improving AAV vector yield in insect cells by modulating the temperature after infection. Biotechnology and Bioengineering, 2007, 97, 1501-1509.	1.7	27
96	Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification. Biotechnology and Bioengineering, 2007, 98, 789-799.	1.7	113
97	Exploiting heparin-binding properties of MoMLV-based retroviral vectors for affinity chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 846, 124-131.	1.2	21
98	Primary recovery and chromatographic purification of adeno-associated virus type 2 produced by baculovirus/insect cell system. Journal of Virological Methods, 2007, 139, 61-70.	1.0	46
99	High yield purification of functional baculovirus vectors by size exclusion chromatography. Journal of Virological Methods, 2007, 142, 21-28.	1.0	50
100	Scalable serum-free production of recombinant adeno-associated virus type 2 by transfection of 293 suspension cells. Journal of Virological Methods, 2007, 144, 32-40.	1.0	77
101	Validation of a high-performance liquid chromatographic assay for the quantification of Reovirus particles type 3. Journal of Pharmaceutical and Biomedical Analysis, 2007, 45, 417-421.	1.4	5
102	Virus-like Particle and Viral Vector Production Using the Baculovirus Expression Vector System/Insect Cell System. Methods in Molecular Biology, 2007, 388, 281-296.	0.4	16
103	Stability of Serum-Free and Purified Baculovirus Stocks under Various Storage Conditions. Biotechnology Progress, 2006, 22, 319-325.	1.3	61
104	Multivariable Nonlinear Control of Biomass and Metabolite Concentrations in a High-Cell-Density Perfusion Bioreactor. Industrial & Engineering Chemistry Research, 2006, 45, 8985-8997.	1.8	21
105	Large-Scale Transfection of Mammalian Cells for the Fast Production of Recombinant Protein. Molecular Biotechnology, 2006, 34, 225-238.	1.3	203
106	Downstream processing of oncoretroviral and lentiviral gene therapy vectors. Biotechnology Advances, 2006, 24, 321-337.	6.0	83
107	Purification and characterization of retrovirus vector particles by rate zonal ultracentrifugation. Journal of Virological Methods, 2006, 133, 82-91.	1.0	41
108	Analysis of baculovirus aggregates using flow cytometry. Journal of Virological Methods, 2006, 134, 8-14.	1.0	29

#	Article	IF	CITATIONS
109	Retroviral vector production using suspension-adapted 293GPG cells in a 3L acoustic filter-based perfusion bioreactor. Biotechnology and Bioengineering, 2006, 95, 653-660.	1.7	30
110	Production of adeno-associated viral vectors in insect cells using triple infection: Optimization of baculovirus concentration ratios. Biotechnology and Bioengineering, 2006, 95, 1081-1092.	1.7	47
111	A novel purification strategy for retrovirus gene therapy vectors using heparin affinity chromatography. Biotechnology and Bioengineering, 2005, 90, 391-404.	1.7	77
112	Purification of recombinant proteins from mammalian cell culture using a generic double-affinity chromatography scheme. Protein Expression and Purification, 2005, 40, 77-85.	0.6	46
113	Acoustic cell filter: a proven cell retention technology for perfusion of animal cell cultures. Biotechnology Advances, 2004, 22, 433-444.	6.0	59
114	Insights into adenoviral vector production kinetics in acoustic filter-based perfusion cultures. Biotechnology and Bioengineering, 2004, 86, 765-774.	1.7	76
115	Development and optimization of an adenovirus production process. Journal of Gene Medicine, 2004, 6, S184-S192.	1.4	168
116	High-performance liquid chromatographic total particles quantification of retroviral vectors pseudotyped with vesicular stomatitis virus-G glycoprotein. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 813, 167-173.	1.2	17
117	Micro-quantitation of lipids in serum-free cell culture media: a critical aspect is the minimization of interference from medium components and chemical reagents. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 810, 119-127.	1.2	7
118	Production of adenovirus vector for gene therapy. Biotechnology Advances, 2003, 20, 475-489.	6.0	135
119	Large-scale transient transfection of serum-free suspension-growing HEK293 EBNA1 cells: Peptone additives improve cell growth and transfection efficiency. Biotechnology and Bioengineering, 2003, 84, 332-342.	1.7	125
120	Improving Glucose and Glutamine Metabolism of Human HEK 293 and Trichoplusia ni Insect Cells Engineered To Express a Cytosolic Pyruvate Carboxylase Enzyme. Biotechnology Progress, 2003, 19, 90-97.	1.3	61
121	Size-Exclusion Chromatography Purification of High-Titer Vesicular Stomatitis Virus G Glycoprotein-Pseudotyped Retrovectors for Cell and Gene Therapy Applications. Human Gene Therapy, 2003, 14, 1139-1153.	1.4	69
122	Quantitation of baculovirus particles by flow cytometry. Journal of Virological Methods, 2002, 105, 321-330.	1.0	73
123	High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Research, 2002, 30, 9e-9.	6.5	913
124	Monitoring Motility, Spreading, and Mortality of Adherent Insect Cells Using an Impedance Sensor. Analytical Chemistry, 2001, 73, 1844-1848.	3.2	111
125	Increased Production of Active Human β2-Adrenergic/Gαs Fusion Receptor in Sf-9 Cells Using Nutrient Limiting Conditions. Protein Expression and Purification, 2001, 23, 66-74.	0.6	6
126	Improved high-performance liquid chromatographic method in the analysis of adenovirus particles. Biomedical Applications, 2001, 755, 27-36.	1.7	43

#	Article	IF	CITATIONS
127	Validation of a high-performance liquid chromatographic assay for the quantification of adenovirus type 5 particles. Biomedical Applications, 2001, 761, 187-194.	1.7	26
128	Dystrophin Expression in Muscle Following Gene Transfer with a Fully Deleted ("Gutted") Adenovirus Is Markedly Improved by Trans-Acting Adenoviral Gene Products. Human Gene Therapy, 2001, 12, 1741-1755.	1.4	56
129	Understanding factors that limit the productivity of suspension-based perfusion cultures operated at high medium renewal rates. , 2000, 67, 435-450.		58
130	Enhanced growth of sf-9 cells to a maximum density of 5.2 × 107 cells per mL and production of β-galactosidase at high cell density by fed batch culture. , 2000, 68, 381-388.		76
131	A Reporter Gene Assay for High-Throughput Screening of G-Protein-Coupled Receptors Stably or Transiently Expressed in HEK293 EBNA Cells Grown in Suspension Culture. Analytical Biochemistry, 2000, 284, 316-326.	1.1	118
132	On-Line Monitoring of Physiological Parameters of Insect Cell Cultures during the Growth and Infection Process. Biotechnology Progress, 2000, 16, 803-808.	1.3	55
133	Enhanced growth of sf-9 cells to a maximum density of 5.2 \tilde{A} — 107 cells per mL and production of \hat{I}^2 -galactosidase at high cell density by fed batch culture. , 2000, 68, 381.		1
134	Adaptive Control at Low Glucose Concentration of HEK-293 Cell Serum-Free Cultures. Biotechnology Progress, 1999, 15, 608-616.	1.3	50
135	Adenovirus-Mediated Utrophin Gene Transfer Mitigates the Dystrophic Phenotype of mdx Mouse Muscles. Human Gene Therapy, 1999, 10, 1299-1310.	1.4	108
136	Serum-free production of recombinant proteins and adenoviral vectors by 293SF-3F6 cells. Biotechnology and Bioengineering, 1998, 59, 567-575.	1.7	130
137	A TrkA-selective, Fast Internalizing Nerve Growth Factor-Antibody Complex Induces Trophic but Not Neuritogenic Signals. Journal of Biological Chemistry, 1998, 273, 34933-34940.	1.6	78
138	Study of Adenovirus Production in Serum-Free 293SF Suspension Culture by GFP-Expression Monitoring. Biotechnology Progress, 1997, 13, 709-714.	1.3	51
139	On-line monitoring of respiration in recombinant-baculovirus infected and uninfected insect cell bioreactor cultures. , 1996, 50, 36-48.		114
140	Use of the Centritech Lab Centrifuge for Perfusion Culture of Hybridoma Cells in Protein-Free Medium. Biotechnology Progress, 1996, 12, 855-864.	1.3	54
141	Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells. Cytotechnology, 1994, 15, 145-155.	0.7	117
142	Baculovirus expression system scaleup by perfusion of high-density Sf-9 cell cultures. Biotechnology and Bioengineering, 1994, 43, 881-891.	1.7	48
143	Protein-free culture medium improvement: testing additives and their interactive effects in 96-well plates. Applied Microbiology and Biotechnology, 1993, 39, 577-584.	1.7	3
144	Growth, nutrient consumption, and end-product accumulation in Sf-9 and BTI-EAA insect cell cultures: Insights into growth limitation and metabolism. Biotechnology Progress, 1993, 9, 615-624.	1.3	111

#	Article	IF	CITATIONS
145	Production of Lentiviral Vectors Using a HEK-293 Producer Cell Line and Advanced Perfusion Processing. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	12